VILTEPSO® HCP Resources | Patient Access & Downloads

Expand

Collapse

Indication & Important Safety Information

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

Warnings and Precautions: Kidney toxicity was observed in animals who received viltolarsen. Although kidney toxicity was not observed in the clinical studies with VILTEPSO, the clinical experience with VILTEPSO is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VILTEPSO. Serum creatinine may not be a reliable measure of kidney function in DMD patients.

Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. Consider also measuring glomerular filtration rate before starting VILTEPSO. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months.

Urine should be free of excreted VILTEPSO for monitoring of urine protein. Obtain urine either prior to VILTEPSO infusion, or at least 48 hours after the most recent infusion. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, which has the potential to generate a false positive result due to cross reaction with any VILTEPSO in the urine. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

Adverse Reactions: The most common adverse reactions include upper respiratory tract infection, injection site reaction, cough, and pyrexia.

To report an adverse event, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM
(1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.

Privacy Notice|Terms of Use|Contact Us |Cookie Settings

NS Pharma, the NS Pharma symbol, and VILTEPSO are registered trademarks of Nippon

Shinyaku Co., Ltd. The NS Support logo is a registered trademark of NS Pharma, Inc.

04/26 | US-NS65C-1930

VILTEPSO Resources

Support for Healthcare Providers

NS Support Patient Access Solutions

Letter of Medical Necessity Tool

Additional VILTEPSO Resources

VILTEPSO HCP Brochure

VILTEPSO Dosing & Administration Guide

Request a Representative

About VILTEPSO

Efficacy & Safety

Dosing & Administration

Indication

Important Safety Information